ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Moderna Therapeutics, the Cambridge, Mass.-based messenger RNA (mRNA) therapeutics start-up, has opened a $110 million, 18,600-m2 production facility. The plant will house over 200 employees and make mRNA molecules for the company’s clinical programs, including its ischemic heart disease partnership with AstraZeneca. The plant will also make mRNA for Moderna’s vaccine programs, including vaccines for infectious diseases, mosquito-borne diseases, and cancer.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter